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ABSTRACT
Cheemarla, Nagarjuna Reddy. M.S. Department of Microbiology and Immunology, Wright State
University, 2013. SOCS1/SOCS3 Expression and Cytokine Characterization in HSV-1 and
DENV2 Infected Macrophage Subsets.

Cytokine activation of macrophages leads to “macrophage polarization” The M1 subset is
polarized by exposure to lipopolysaccharide (LPS) and interferon-gamma (IFN-) and
M2 polarized cells develop after exposure to interleukin-4 (IL-4) or IL-13. In this study,
the RAW 264.7 murine macrophage cell line was used to study the effect herpes simplex virus –
Type I (HSV-1) and Dengue virus serotype-2 (DENV2) infections have on cultures of
unpolarized (M0) or polarized subsets. The macrophage subsets were characterized using cluster
of differentiation markers CD14 and CD86. Uninfected M1 macrophages showed up

regulation in expression of the co-stimulatory factor B7.2 (CD86) compared to
expression by M0 or M2 macrophages. M1 macrophages exhibited distinct
morphological and viability features including presence of vacuoles, strong adherence,
enlargement of cell body and significant decrease in cell viability at 24 hours following
exposure to LPS and IFN-. Infection with either HSV-1 or DENV-2 induced a down
regulation in expression of CD86 by M1 cells and an up-regulation of expression in M0
and M21 cells. Immunofluorescence analysis using flow cytometry showed a decrease in
CD86 expression levels in only M1 cells by 24 hours following infection with either
infected with HSV-1 or DENV2. Virus-infected M1 macrophages showed further
decreases in cell viability compared to viabilities of infected M0 or M2 macrophages. In
iii

unpolarized and polarized macrophages in this study, SOCS 3 expression was highest in
M0 and M2 cell prior to and after infection with either HSV-1 or DENV2. In these same
cell populations higher cell viabilities were observed at 12 and 24 hours after infection as
well as higher viral titers by 24 hours post infection. In contrast, the M1 macrophage
populations showed lesser increases in SOCS 3 expression, markedly decreased cell
viabilities and 2.8fold decrease in viral titers by 24 hour after infection with HSV-1.
These observations suggest that the ameliorating effect of SOCS3 on inflammation in the
M0 and M2 macrophages permitted both a slower decline in cell viabilities and enhanced
viral replication in these isolated cell populations. Cells converted to the M1 phenotype
rapidly diminished viral replication and cell viability.
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HYPOTHESIS

The hypothesis of this study was that the M1 subpopulation of murine RAW 264.7 cells in
comparisons with the M0 and M2 subpopulations would exhibit significant decreases in cell

viability but greater ability to control viral replication by 24 hours following infection
either HSV-1 or DENV2; and these difference could be related to relative expression of
suppressors of cytokine signaling 1 and 3 (SOCS1 and SOCS3).

v

TABLE OF CONTENTS

INTRODUCTION...............................................................................................................1
LITERATURE REVIEW AND PRELIMINARY DATA..................................................5
Dengue Virus and Infection....................................................................................5
Macrophages and Dengue Infection…....................................................................6
Macrophage Function and Activation......................................................................7
Herpes Simplex Virus and Infection......................................................................10
Cluster of Differentiation (CD) Markers................................................................10
SOCS Proteins........................................................................................................11
MATERIALS AND METHODS........................................................................................16
Cell Lines...............................................................................................................16
Polarization Treatment...........................................................................................16
Virus Culture and Quantification............................................................................17
Cell Viability..........................................................................................................18
Immunofluorescent Staining..................................................................................19
Flow Cytometry Analysis......................................................................................20
vi

Western Blotting.....................................................................................................21
Calculation of Viral Titers in HSV-1 Infected Macrophage Subsets.....................21
Statistical Analysis..................................................................................................22
RESULTS............................................................................................................................23
DISCUSSION......................................................................................................................29
FIGURES.............................................................................................................................34
REFERENCES.....................................................................................................................67

vii

LIST OF FIGURES

Figure 1: Two Loop Model of DENV Antibody Dependent Enhancement..................9
Figure 2: Structure of SOCS Proteins............................................................................13
Figure 3: Suppression of TLR and Interleukin Pathways by SOCS…..........................14
Figure 4: DENV2 Plaque Assay.....................................................................................34
Figure 5: Morphological Changes exhibited by RAW 264.7 macrophage
sub-populations 12 hours post cytokine treatment with or without infection…............35
Figure 6: RAW 264.7 Macrophage Morphology and Actin Arrangement Following
Polarization……………………………….……………………………………………36
Figure 7: M1 Macrophages Exhibiting Multiple Intracellular Vacuoles.......................37
Figure 8: Immunofluorescent Images of Uninfected Control (Untreated) Macrophages
Stained with anti- CD14, anti-CD86, and Phalloidin………………………………....38
Figure 9: Immunofluorescent Images of Uninfected M1 Macrophages Stained with antiCD14, anti-CD86, and Phalloidin...................................................................................39
Figure 10: Immunofluorescent Images of Uninfected M1 Macrophages Stained with antiCD14, anti-CD86, and Phalloidin...................................................................................40
Figure 11: Flow Cytometry Analysis of CD14-CD86 Expression Levels in M1, M2, and
viii

Control Macrophages......................................................................................................41
Figure 12: CD14/CD86 Expression Profile in Uninfected Control,
M1 and M2 Macrophages……………………………………………………………...42
Figure 13: Cell Viability of Uninfected, HSV-1 or DENV2 Infected Macrophage Subpopulations
After 12 Hours..................................................................................................................43
Figure 14: Cell Viability of Uninfected, HSV-1 or DENV2 Infected Macrophage Subpopulations
After 24 Hours..................................................................................................................44
Figure 15: Morphological Changes Exhibited by RAW 264.7 Macrophage Sub-populations 24
Hours Post Cytokine Treatment and HSV-1 Infection.....................................................45
Figure 16: Enlarged M2 Macrophages Post HSV-1 Infection..........................................46
Figure 17: Immunofluorescent Images of HSV-1 infected Control (Untreated) Macrophages
Stained with anti- CD14, anti-CD86, and Phalloidin……………………........................47
Figure 18: Immunofluorescent Images of HSV-1 infected M1 Macrophages Stained with antiCD14, anti-CD86, and Phalloidin......................................................................................48
Figure 19: Immunofluorescent Images of HSV-1 infected M2 Macrophages Stained with antiCD14, anti-CD86, and Phalloidin.......................................................................................49
Figure 20: Flow Cytometry Analysis of CD14-CD86 Expression Levels in HSV-1 infected M1,
M2, and Control Macrophages ..........................................................................................50

ix

Figure 21: CD14/CD86 Expression Profile in HSV-1 Infected Control, M1 and M2
Macrophages………………………………………………………………………………..51
Figure 22: Morphological Changes Exhibited by RAW 264.7 Macrophage Sub-populations 24
Hours Post Cytokine Treatment and DENV2 Infection.........................................................52
Figure 23: Immunofluorescent Images of DENV2 Infected Control Macrophages Stained with
anti-CD14, anti-CD86, and Phalloidin...................................................................................53
Figure 24: Immunofluorescent Images of DENV2 Infected M1 Macrophages Stained with antiCD14, anti-CD86, and Phalloidin..........................................................................................54
Figure 25: Immunofluorescent Images of DENV2 infected M2 Macrophages Stained with antiCD14, anti-CD86, and Phalloidin.........................................................................................55
Figure 26: Flow Cytometry Analysis of CD14-CD86 Expression Levels in DENV2 infected M1,
M2, and Control Macrophages.............................................................................................56
Figure 27: CD14/CD86 Expression Profile in DENV2 Infected Control, M1 and M2
Macrophages………………………………………………………………………………57
Figure 28: SOCS1 Expression in RAW 264.7 Macrophages after 12 Hours of Cytokine Treatment
with or without Virus Treatment..........................................................................................58
Figure 29: SOCS3 expression in RAW 264.7 Macrophages after 12 Hours of Cytokine Treatment
with or without Virus Treatment..........................................................................................59

x

Figure 30: SOCS1 expression in RAW 264.7 Macrophages after 24 Hours of Cytokine Treatment
with or without Virus Treatment........................................................................................60
Figure 31: SOCS3 expression in RAW 264.7 Macrophages after 12 Hours of Cytokine Treatment
with or without Virus Treatment........................................................................................61
Figure 32: SOCS1/SOCS3 ratio in RAW 264.7 Macrophages after 12 Hours of Cytokine
Treatment with or without Virus Treatment......................................................................62
Figure 33: SOCS1/SOCS3 ratio in RAW 264.7 Macrophages after 24 Hours of Cytokine
Treatment with or without Virus Treatment......................................................................63
Figure 34: HSV-1 Titers in Infected Macrophage Subsets ...............................................66

xi

LIST OF FIGURES

Table 1: Cell viability percentages...............................................................................................64
Table 2: SOCS protein expression percentages............................................................................65

xii

LIST OF ABBREVIATIONS

WBC= White Blood Cells
LPS= Lipopolysaccharide
IFN-γ= Interferon gamma
NO= Nitric Oxide
HVEM= Herpes Virus Entry Mediator
GAGs= Glycosaminoglycans
GM-CSF= Granulocyte Macrophage Colony Stimulating Factor
CD= Cluster of Differentiation
SOCS= Suppressor of Cytokine Signaling
ADE= Antibody Dependent Enhancement

xiii

ACKNOWLEDGEMENT

I would like to thank my advisor, Dr. Nancy J. Bigley, for her patience, guidance,
and unrelenting support in the completion of this project. I appreciate having the
opportunity to learn about Immunology from one of the best. I would like to thank my
program director, Dr. Barbara Hull and Dr. Eric M. Vela for being on my committee and
for their valuable suggestions toward my thesis.
I would like to thank all my fellow lab members especially Noura for helping me
in viral quantification experiments. I would also like to thank WSU Graduate Student
Assembly for their financial contribution to my work.
Lastly, I would like to thank my parents and friends especially Ramya, for all the
love, support and encouragement.

xiv

INTRODUCTION

Dengue virus is a positive single-stranded RNA virus that belongs to the
Flaviviridae family of viruses (Rodenhuis-Zybert et al., 2010). Dengue viral infection
occurs in sylvatic cycles. The sylvatic cycle refers to the population of pathogen’s life
span spent cycling between wild animals and the vector. Humans are a dead-end host of
this virus life cycle (Fernandes et al., 1999).
Dengue virus initiates both innate and adaptive immune responses. Dengue virus nonstructural (NS) proteins have the ability to inhibit innate immune response during
infection. These non-structural proteins inhibit the innate responses at two-levels:
1) Inhibition of interferon signaling by blocking signal transducer:
NS4, a membrane protein associated with endoplasmic reticulum, inhibits the
phosphorylation of STAT1 after induction by type I interferons (IFN) alpha, beta.
Consequently, immune response are blocked and interferon stimulated genes
(ISG) are not expressed. With dengue virus infection, Tyk2 kinase activity
decreases resulting in a decrease in STAT1 phosphorylation (Ho et al., 2005).
Also, NS2A and NS4A cofactors take part in STAT inhibition (Muñoz-Jordan et
al., 2003). NS5A is a 105KDa protein that inhibits activation of STAT2 and is
cleaved by a protease. This cleaved NS5A binds to STAT2 via an E3 ligase
association, which degrades STAT2 (Mazzon et al., 2009; Morrison et al., 2012).
1

2) Inhibition of Type I interferon response:
NS2B3 is a protease complex core that consists of partly both NS2B and NS3
proteins (Yusof et al., 2000). This complex inhibits the production of IFN-β by
interfering with the activity of IFN- β promoter by inhibiting phosphorylation of
IRF3 (Rodriguez-Madoz et al., 2010; Yu et al., 2012).
Herpes simplex virus infection also triggers the immune regulation pathways in
the host. Although primary infection by HSV is usually undetectable, the virus persists in
a latent infection within the host and can be stimulated by a secondary infection at a later
point. The virus remains in the trigeminal ganglia during latency and show minimal virus
gene expression (Rautemaa et al., 2002). The immune responses triggered by HSV
infection mainly involve three cells: macrophages, natural killer cells (NK) and γ/δ T
cells. These cells are recruited to the site of infection by chemotactic cytokines. These
cells then prevent viral replication and eliminate infected cells (Cunningham et al., 2006;
Mikloska et al., 1998).
Macrophages are “phagocytic” cells and express a variety of surface receptors that
are activated by many signals. Both HSV and DENV infection involves recruitment of
macrophages to the site of infection upon cytokine signaling. DENV has affinity for FcγR
expressing cells such as dendritic cells and macrophages. Macrophages play a crucial role
in controlling viral replication. They can themselves inhibit viral replication when
infected. They signal extracellular viral proteins for degradation via proteasome and
2

ubiquitylation and kill virus-infected cells attenuating viral replication (Wu and Morahan,
1992). At the time of viral infection signaling molecules such as cytokines are produced
that act as signals to activate the receptor thus altering the structure and functions of
macrophages by characterizing them into different subpopulations (Murray and Wynn,
2011). Cytokine activation of macrophage subpopulations is referred to as “macrophage
polarization”. Unstimulated macrophages are called M0 macrophages. M1 macrophages
are produced by signal such as bacterial lipopolysaccharides (LPS) and interferon-γ and
produce pro-inflammatory cytokines such as iNOS, TNF-α and IL-12. They are
mobilized by infectious agents and hence promote inflammation. A variety of cytokine
trigger polarization to M2 macrophages especially IL-4 and IL-13. M2 macrophages on
the other hand produce anti-inflammatory cytokines such as IL-10, Arg-1 and IL-4 that
are involved in wound healing and tissue repair (Junliang et al., 2010; Kigerl et al., 2009;
Wang et al., 2010). The different macrophage subpopulations express variations in cluster
of differentiation markers (CD markers) on the cell surface. The CD markers essential for
differentiating M1 and M2 macrophage subpopulations are CD14 and CD86. CD14 acts
as a co-receptor along with TLR4 and detects LPS. CD86 is expressed on antigen
presenting cells and is involved in B cell stimulation, antigen presentation to activate T
cell signaling and survival (Sugamura et al., 2004).
Another factor that influences viral infection and immune responses in the host is
Suppressor of cytokine signaling (SOCS) proteins. Under normal conditions, SOCS
proteins act in an anti-inflammatory manner involve ubiquitylation and degradation of
3

inflammatory proteins while maintaining antipathogenic functions (Kubo et al., 2003).
When the host cells are infected by viruses, these SOCS proteins become the targets for
viral evasion. The virus implements robust mechanisms to “hijack” SOCS functions to
promote virus survival and replication in the host. SOCS proteins inhibit antiviral
pathways thus allowing the viral proteins to be taken up by the cells, subjecting these
proteins to ubiquitylation, facilitates viral trafficking, progeny virus assembly and
increase in the copy number of virions (Lisa and Benveniste, 2011).
The overall process of viral infection, macrophage polarization, surface receptor
expression and SOCS protein function varies from macrophage to macrophage and
different viruses that infect. The current study shows these differences in RAW 264.7
macrophages upon infection with either DENV or HSV. And the variation in responses
between J774.1 macrophages from earlier findings and RAW264.7 macrophages is
discussed.
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LITERATURE REVIEW AND PRELIMINARY DATA

Dengue Virus and Infection
Dengue virus (DENV) belongs to the Flaviviridae family of viruses. DENV
infection is an arthropod-borne disease. There are 4 serotypes of DENV, including
serotypes- 1 through -4 are transmitted from person to person by Aedes aegypti and Aedes
albopictus mosquitos (Gubler and Kuno, 1997). Dengue is a Center for disease control
(CDC) category A infectious disease. Dengue disease presents in three clinical forms:
Dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). Over 2.5 billion people are living in areas at risk of Dengue infection [WHO
factsheet 2012]. The number of deaths by Dengue Hemorrhagic fever has increased
rapidly in the past decade. Approximately more than 50 million cases take place each
year, associated with more than 25,000 fatalities, especially in children (WHO factsheet
2002). Still there is neither a vaccine nor a specific treatment for Dengue.
This Flavivirus is composed of three structural proteins or glycoproteins: the C
protein, which forms the nucleocapsid containing viral genome, and proteins M and E,
which are inserted into the lipid membrane surrounding the nucleocapsid. The genome of
DENV is composed of a single-stranded RNA of ~11Kb. The E protein is expressed on
the surface and is responsible for binding and entry of virus into the cell. It is also the
neutralization antigen and is responsible for variability of the four major serotypes DENV
1-4 (Kuhn et al., 2002). Dengue infection occurs in three stages: 1) mosquito injects the
5

dengue virus into the human body and enters the dendritic cells (specialized cells present
in most tissues); 2) Dengue virus targets primary monocytes/macrophages in spleen, bone
marrow and glands; 3) entering the monocytes and lymphatic system, allows the dengue
virus to enter the circulatory system and spread throughout the body.

Macrophages and Dengue Infection
When a person is infected for the first time with DENV, both humoral and
cellular immunity develop into action. The humoral response produces many neutralizing
antibodies necessary to prevent the virus from fusing with cell membrane. The cellular
response involves activation of T lymphocytes by the dendritic cells carrying the dengue
virus, which help fight off primary infection and development of serotype-specific
memory B cells. These memory cells have the ability to fight off any future infections by
the same serotype (Ho et al., 2001).
In vivo, the predominant site of DENV infection is the cells of mononuclear
phagocyte lineage (Scott et al., 1980; Halstead, 1989). In case of a secondary infection by
a different serotype, the memory B cells produce antibodies that accelerate the process of
dengue infection and onset of hemorrhagic fever by increasing viral uptake (Dimmock,
2007). The prevailing theory is that, the non-neutralizing antibodies of a different
serotype tries to fight off the new serotype, but actually cross-react and form a complex
with the virus. This complex is internalized by the macrophages with the help of Fc
receptors and the virus multiplies rapidly in these infected macrophages, thus speeding up
6

the process of infection (Fig 1). In case of dengue infection, there is increased release of
pro-inflammatory cytokines. This increased release and accumulation of cytokines result
in vascular permeabilization and hence plasma leakage, a symptom of DHF (Ho et al.,
2001). This type of immune system response to a secondary infection is called antibody
dependent enhancement (ADE). Due to plasma leakage occurs internal bleeding and
thrombosis results. After continuous release of platelets and increasing bleeding,
disseminated intravascular coagulation occurs. This results in hemorrhage and a “glitch”
in the circulatory system resulting in shock and ultimately death of a person (WHO,
1999).

Macrophage Function and Activation
Macrophages are phagocytic cells that are produced by differentiation of
monocytes in the tissues.
Two types of T-helper CD4+ cell responses are induced by antigen presenting
cells, namely Th1 and Th2 respectively. The Th1 response is characterized by activation
of bactericidal activities of macrophages and release of pro-inflammatory cytokines such
as IFN-. Th2 responses on the other hand, are characterized by the release of antiinflammatory cytokine such as interleukin-4 (IL-4) and activation of B cells to produce
neutralizing antibodies. The CD4+ Th cell differentiation is analogous to the macrophage
polarization pathways that are designated M1 and M2 (David, Mosser and Justin, 2008).
M1 macrophages are activated by LPS and IFN-and known as immune effector cells
7

that act against microbes, digest affected cells and produce many lymphokines. M1
macrophages produce pro-inflammatory cytokines such as IL-1 IL-12 and TNF-, as
well as reactive oxygen species, NO and mediate resistance to tumors (Mantovani et al.,
2004; Goerdt et al., 1999; Mantovani et al., 2005; Mills et al., 2000). While M2
macrophages produce anti-inflammatory cytokines such as IL-10, contribute to Th2
responses, promotes tissue repair, induce proliferation, collagen production, and enhances
phagocytosis and parasite elimination (Fadok et al., 1998; Munder et al., 1998; Porcheray
et al., 2005). The M2 macrophages are classified into M2a, M2b and M2c depending
upon specific factors of stimulation or activation. M2a are stimulated by IL-4, M2b by
TLR and IL-1ra and M2c by IL-10 (Mantovani et al., 2004). M2 macrophages are
thought to be tumor- associated macrophages and produce high IL-10 and low IL-12
unlike M1 macrophages that produce high IL-12 and low IL-10 (Galdiero et al., 2013).
The substrate for both the pathways is the same, an amino acid called arginine. Nitrous
oxide synthase (NOS) induced by LPS and IFN-produces HO-Arginine and then NO.
While the Th2 cytokines convert arginine into ornithine and eventually polyamines and
proline (Classen et al., 2009).
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Figure 1. Two-loop model of antibody dependent enhancement. DENV-subneutralization
antibody complex ligates with the FcγR and induces suppression of innate immune
responses. This is done by two different pathways:
1) Negative regulators of PPR, DAK, Atg5 to Atg12, SARM and TANK are
upregulated, that abolish RLR and TLRs and its signaling pathway, resulting in
decreased type 1 interferon receptor and pro-inflammatory cytokine production,
which suppresses IFN –mediated antiviral responses
2) IL-10 that activates SOCS system is subject to early activation, suppressing the
JAK/STAT signaling pathway and also the IFN-signaling pathway.
These two loops switch off the intracellular antiviral responses in DENV-infected
cells under the influence of ADE conditions, resulting in viral replication and increase
in copy number of virions. (Adapted from Ubol and Halstead, 2010)
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Herpes Simplex Virus and Infection
Herpes simplex virus belongs to the Herpesviridae family (Ryan and Ray, 2004).
HSV contains a double-stranded, linear DNA genome enclosed in a protein capsid
wrapped by an envelope. HSV enters the cells with the help of glycoproteins gC and gD,
the former helps in attaching to the host cells and the latter helps in entry into the host
cells via interactions with one of the three cell surface receptors namely HVEM, nectin-1
and 3-O sulfated heparan sulfate. When gD binds to HVEM, gD changes its
conformation and interacts with gH and gL which forms a complex. Another
glycoprotein gB interacts with gH/gL complex to form a virus capsid entry pore by
interfering with the GAGs in the cell wall of the host cells (Subramanian and Geraghty,
2007). After viral entry into the cell, the viral genome is transmitted by microtubules into
the host genome by entry into the nucleus through a nuclear entry pore (Newcomb et al.,
2007).
HSV blocks the transporter associated with antigen processing (TAP) through
release of ICP-47. The viral ICP-47 on the other hand inhibits TAP, thus inhibiting the
activation of CTLs and allowing the virus to stay active for a longer period (Mojadadi et
al., 2009).

Cluster of Differentiation (CD) Markers
CD markers are a critical factor to differentiate M1 macrophages from M2. This is
done by studying the number cells expressing the cell surface receptors cluster of
10

differentiation 14 (CD14) and CD86. CD14 is essential as it acts as a co-receptor along
with Toll-like receptor 4 (TLR4) and MD-2 and detects bacterial LPS. It is known to bind
to LPS with the help of LPS binding protein (LBP) and is involved in the activation of
many transcription factors. CD86, also known as B7-2 is expressed on antigen presenting
cells that is involved in B cell co-stimulation, T cell activation and survival. CD86 also
acts as a counter-receptor for CD28 (Sugamura et al., 2004). Some of the earlier findings
in our lab suggest that CD14+CD86+ cells are higher in M1 polarized macrophages than
the control macrophages. While cells infected with HSV-1 and polarized to M1 or M2
phenotype show a decrease in the percent of CD14-CD86 positive cells. This study is to
show the effect of HSV1, DENV2 infection and cytokine induced polarization on
RAW264.7 macrophages and their CD markers CD14 and CD86.

SOCS Proteins
Suppressor of cytokine signaling (SOCS) are proteins that inhibit cytokine
signaling pathways. They are involved in both innate and adaptive immunity and regulate
the macrophages and dendritic cells and play an important role in T cell development and
differentiation (Yoshimura, 2007). There are eight subtypes of SOCS proteins (SOCS1SOCS 7 and CIS) that have a –SH2 domain and C-terminal SOCS box (Fig 2).
The expression of SOCS1-3 and CIS is stimulated by various cytokines and these
are known to regulate pathways such as JAK/STAT pathway (Fig 3). These SOCS
proteins are known to implement one or more of the three mechanisms: 1) binding to
11

phosphotyrosines through SH2 domain resulting in N-terminal inactivation of JAK; 2)
blocking receptor binding sites of STAT; 3) by SOCS box-targeting bound proteins to
ubiquitylation.

12

Figure 2. Structure of SOCS proteins. SOCS proteins contains three domains namely,
kinase inhibitory region (KIR), SH2 domain and the SOCS box. KIR is involved in
inhibiting the phosphorylation and activation of JAK by acting as a pseudosubstrate. SH2
domain binds to phosphotyrosine residues and causes N-terminal inactivation of JAK.
The SOCS box is a crucial component that signals that target proteins for degradation by
ubiquitylation upon interaction with complex comprising of Elongin B, Elongin C,
RBX2, Cullin-5 and E2 ligase. (Adapted from Yoshimura et al., 2007)
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Figure 3. Suppression of TLR and Interleukin pathways by SOCS. LPS activates
TLR4 that transmits signals through adaptor proteins MyD88, MyD88-adaptor-like
protein (MAL), TIR domain-containing adaptor inducing interferon (TRIF) and TRAM.
Then TRAF6 is activated that activates NF-κB and MAPK pathways thus activating proinflammatory cytokines. TRIF and TRAM activate JAK2/STAT5 pathway that produces
IL-6 and also activates TRIF/IRF3 pathway that produces Type I interferons. These Type
I interferons activate the JAK/STAT1 pathway producing CD40, iNOS and IFNinducible genes. The IL-1R signals MyD88 to activate TRAF6, TAK1 and ultimately
produce pro-inflammatory cytokines by NF-κB and MAPK pathways. Phosphorylated
MAL interacts with SOCS1 resulting in MAL polyubiquitylation and degradation.
SOCS3 inhibits the association between TRAF6 and TAK1 thus inhibiting NF-κB
dependent transcription. (Adapted from Yoshimura et al., 2007)
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SOCS1 is stimulated by cytokines IL2, EPO, IFN-γ and GM-CSF. It acts as a
negative regulator of IFN-γ and JAK-STAT pathway as it acts through a negative
feedback loop to inhibit the JAK-STAT pathway (Minamoto et al., 1997).
SOCS3 proteins are induced by cytokines such as IL6, IL10 and IFN-γ. They
inhibit the activity of JAK2-kinase (Minamoto et al., 1997). Both SOCS1 and SOCS3
encode the STAT-induced STAT inhibitor (SSI) gene. It is also shown that SOCS1 is
expressed more in IL-4 induced M2 macrophages than pro-inflammatory M1
macrophages (Whyte et al., 2011). The SOCS proteins mainly SOCS1 and SOCS3
additionally have a Kinase inhibitory region (KIR) upstream of the central SH2 domain
that acts as a pseudosubstrate. SOCS1 inhibits the catalytic activity of JAK by binding to
the activation loop through its KIR and SH2 domains (Yoshimura, 2007).
From Reichard’s study, we know that SOCS1 expression is enhanced in HSV-1
infected M1 macrophages more than in HSV1 infected M2 macrophages. This study
involves studying the effect of cytokine-induced polarization to RAW 264.7 cells
infected with HSV-1 and DENV2. The SOCS1/SOCS3 expression ratio in polarized
macrophages and virus treated polarized macrophages were significantly different with
SOCS1/SOCS3 ratio being higher in M1 polarized uninfected cells, while the ratio is
higher in control cells with virus infected polarized macrophages.
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MATERIALS AND METHODS

Cell Lines
The RAW 264.7 murine macrophage cell line (ATCC: TIB 71) is established
from a tumor induced by Abelson murine leukemia virus in male BALB/c mouse are
adherent in nature. RAW 264.7 macrophages were cultured in 100mm x 20mm cell
culture treated petri dishes (BD Biosciences) and incubated at 37°C and 5% CO2 in a
humidified incubator. Cells were cultured and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) (HyClone) supplemented with 10% heat inactivated fetal
bovine serum (FBS) (Fisher brand) and antibiotics (0.1% gentamycin (100000U/mL) and
1% pencillin-streptamycin (10000U/mL Penicillin and 10000U/mL Streptamycin)). Cells
were sub-cultured every two days at a ratio of 1:6. Vero 76 cells (CCL-81, ATCC) are
African green monkey kidney epithelial cells and were used in this study for propagating
viruses and calculating their titers.

Polarization Treatment
RAW 264.7 macrophages at approximately 50% confluence were polarized to
either M1 or M2 phenotypes by respective cytokine treatments. M1 phenotype was
induced using 20 ng/ml of IFNγ (Peprotech) and 100ng/ml of LPS (Chondrex) and M2
phenotype was induced using 20 ng/ml of IL-4 (Peprotech). Cytokine treatment for both
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the phenotypes continued for 24 hours after which the cells were collected using a
dissociation reagent (Cell Stripper by Gibco) and used for further analysis.

Virus Culture and Quantification
Herpes Simplex Virus-1 strain Syn 17+ initially obtained from Dr. Nancy Sawtell,
Children’s Hospital Medical Center, Cincinnati, OH was propagated on confluent
monolayers of Vero cells. After 4-5 days post infection or when CPE was evident, the
cells were spun down, supernatant was aliquoted and stored at -80⁰C. Virus was
quantified by infecting Vero cell monolayers with different dilutions of virus and plaque
forming units were counted to calculate volume required for 0.1 multiplicity of infection
(MOI).
Propagation of DENV serotype 2 (DENV-2) (Dr. Eric M. Vela, Battelle Research
Center) was done on Vero 76 cells. Brieﬂy, Vero 76 cells grown in 100 mm petri dishes
to a conﬂuence of approximately 85% at 37 °C, were infected with DENV-2 for 5-6 days
or until CPE was evident. Cells were then scraped and centrifuged at 1500 rpm to
eliminate cell debris. The supernatant was aliquoted and stored at −80°C until use.
Dengue virus titers were determined by plaque assay in conﬂuent monolayers of Vero 76
cells grown in 6-well plates. Vero 76 cells were inoculated with ten-fold serial dilutions
when monolayers reached 80 to 90% conﬂuence. After 2 h of viral adsorption, the
monolayers were overlaid with 2 ml of Opti-MEM GlutaMAX (Life Technologies Inc.)
containing 2% Methyl-cellulose (Acros Organics) and 0.5% fetal bovine serum. The
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cultures were incubated at 37 °C for 5-6 days and then counted for plaque formation after
ﬁxation with 4% paraformaldehyde and staining with 1% crystal violet solution (Sigma).
Additionally viral titers were also determined using flow cytometry (Fig 4) as described
in F Medina and Juan F. Medina et al, 2012. Briefly, Vero cells grown in 24-well plates
at a density of 1.25 x 105 per well one day prior to infection were infected with ten-fold
serial dilutions of DENV2 diluted in Opti-MEM. After incubating one hour with gentle
rocking every 15 minutes, the supernatant was aspirated and overlaid with 1ml of 2%
methyl cellulose and incubated at 37 °C for 24 hours. Next day, infected monolayers
were trypsinized, fixed, blocked for unspecific binding and then stained with DENV2
monoclonal antibody 4G2 (Millipore). These antibodies are directed to the E protein of
the dengue virus and are capable of specifically neutralizing DENV2 serotype. Because
these antibodies are not fluorescent tagged, the cells were stained with FITC conjugated
secondary antibodies (Biolegend) and analyzed using Accuri C6 flow cytometer. Final
viral titers were calculated as infectious units (IU)/ml.

Cell Viability
RAW 264.7 cells were sub cultured at a ratio of 1:6 and incubated for 12 or 24
hours. At this time, the flasks were approximately 40-50% confluent. They were then
treated with either IFN-γ/LPS for M1 or IL-4 for M2 phenotype polarization with or
without virus (HSV-1 or DENV2). After 12 or 24 hours of treatment, cells were detached
from the cell culture flask using a dissociation reagent. Trypan blue staining was used to
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determine the cell viability using a hemocytometer. Cell Stripper and Trypan Blue were
purchased from Fisher Scientific.

Immunofluorescent Staining
RAW 264.7 cells were grown on cover slips (Fisher Scientific) to approximately
40% confluence. Cells were then treated with IFN-γ and LPS for M1 or IL-4 for M2 with
or without virus for 24 hours. Following treatment, growth medium was aspirated and
cells were rinsed three times with 1% bovine serum albumin (BSA) suspended in
phosphate buffered saline (PBS). Cells were then fixed using 4% Paraformaldehyde in
PBS for 15 minutes and permeabilized using Acetone for 10 minutes at -20°C (for
intracellular staining). Cells were blocked for non-specific binding using blocking buffer
(5% serum from species of fluorochrome-conjugated secondary antibody and 3% BSA
suspended in PBS) for one hour. After blocking, fluorochrome-conjugated antibodies and
phalloidin were added at recommended concentrations to the cover slip and incubated
overnight in the dark at 4˚C. Following incubation, cells were rinsed three times with 1%
BSA in PBS. The cover slips were then mounted on glass slides using a drop of
VectaShield fluorescence mounting medium. Slides were then analyzed for antibody
tagged fluorescence using the Olympus Epi-fluorescence Spot Scope. Anti-CD14
(0.25μg/106cells), anti-CD86 (0.25μg/106cells) and isotype control antibodies for
respective antibodies were purchased from BioLegend; Texas Red-Phalloidin X
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(3μl/million cells) was purchased from Life Technologies (Gaithersburg, MD) and
VectaShield mounting medium was purchased from Fisher Scientific.

Flow cytometry Analysis
RAW 264.7 cells were grown in 150mm x 15mm petri dishes (BD Biosciences) to
approximately 50% confluence and then treated with IFN-γ and LPS for M1 or IL-4 for
M2 with or without virus for 24 hours. Following treatment, cells were detached and
counted using a hemocytometer by trypan blue exclusion method. Cells were then rinsed
three times with 1% bovine serum albumin (BSA) suspended in phosphate buffered
saline (PBS). Blocked for non-specific binding using blocking buffer (5% serum from
species of fluorochrome-conjugated secondary antibody or normal goat serum (NGS) and
3% BSA suspended in PBS) for one hour. After blocking, fluorochrome-conjugated
antibodies and were diluted in blocking buffer and added at recommended concentrations
to the cell pellet and incubated in the dark for 1 hour. Following incubation, cells were
rinsed three times with 1% BSA in PBS and pellet re-suspended in sodium azide solution
and analyzed for antibody tagged fluorescence using the Accuri C6 flow cytometer. AntiCD14 (0.25μg/106cells), anti-CD86 (0.25μg/106cells) and isotype control antibodies for
respective antibodies were purchased from BioLegend.
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Western Blotting
Control and polarized cell (uninfected or infected with HSV-1 or DENV-2)
lysates were prepared and suspended in special lysis buffer (SLB) (1mM HEPES, 0.1%
Triton X-100) containing protease inhibitors aprotonin (2mg/ml) and leupeptin (5mg/ml).
Protein concentration was determined using BIORAD protein estimation method and
samples separated by SDS-PAGE using 4-20% gels (Pierce Thermo Scientific) and
western blotted onto polyvinylidine difluoride membranes (Thermo Scientific).
Membranes were blocked with 5% non-fat milk in PBS-Tween 20 (PBST) and probed
with rabbit anti-mouse SOCS1 and SOCS3 antibodies. Actin probing was used as a
control. Goat anti-rabbit conjugated secondary antibodies (Cell Signaling, Boston, MA)
were used to detect primary antibody binding by adding Luminol (Peroxidase substrate)
purchased from Pierce Thermo Scientific. SOCS antibodies were kindly donated by Dr.
Howard M. Johnson from the University of Florida, Gainesville.

Calculation of Viral Titers in HSV-1 Infected Macrophage Subsets
Viral titers were calculated in HSV-1 infected macrophage subsets 24 hours post
infection. Briefly, supernatants of infected subsets (M0, M1 and M2) were collected 24
hours post infection and various dilutions of supernatants were prepared to infect
confluent Vero cell monolayers for 2 hours. Virus supernatants were aspirated after 2
hours and Vero cells overlaid with 1% methyl cellulose in OptiMEM. Plates were stained
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with 0.5% crystal violet upon visualization of plaques. Virus yield in each experimental
group was calculated in terms of PFU/ml.

Statistical Analysis
Sigma Plot 12.0 software was used for calculating statistical significance and
graphical representations. Analysis conditions were compared using t-test, and P values
less than 0.05 were considered statistically significant. All experiments were conducted
in triplicates.
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RESULTS

Uninfected Control and Cytokine Polarized Macrophages
M1 Macrophages Exhibited Morphological Changes Compared to Control or M2
Macrophages
Macrophages were either unpolarized (control) or polarized with LPS+IFN-γ or
IL-4 into M1 or M2 phenotypes respectively. M1 macrophages appeared to be enlarged,
contained intracellular vacuoles, strongly adherent and stellate following treatment with
LPS and IFN-γ for 24 hours (Fig. 7). These changes in M1 macrophages were observed
as early as 12 hours following treatment (Fig. 5). M2 macrophages appeared similar to
control macrophages without any distinct morphological changes (Fig. 6).

CD Marker Profiling of Polarized and Control Macrophages
Immunofluorescence analysis showed upregulation of CD86 (B7-2) in M1
macrophages (Fig 9) compared to control macrophages (Fig 8). M2 macrophages (Fig
10) exhibited very little or no CD86 expression. CD14 expression was found to be similar
among polarized and control cells, hence it was not characterized as a distinct marker for
particular phenotype.
Flow cytomtery analysis showed upregulation of CD86 expression in M1
macrophages compared to control cells. Flow cytometry analysis of CD markers on
uninfected polarized macrophages show that M1 macrophages exhibit upregulation of
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CD14+-CD86+ expression (33.37%, P-value< 0.001) when compared to control
macrophages. Conversely, M2 macrophages showed insignificant changes in CD14+CD86+ expression (1.14%, P-value= 0.319) when compared to untreated control (Fig 11
and 12).

Cell Viability Studies Following Polarization
Cells were either unpolarized or polarized with cytokines for 12 or 24 hours. Cell
viability assay was performed after 12 or 24 hours by Trypan Blue assay. Both M1
(73.76%, P-value< 0.001) and M2 (47.41%, P-value= 0.001) macrophages exhibited
significant decrease in cell viability 12hrs post-cytokine treatment (Fig 13). M1
macrophages exhibited significant decrease (~85%, P-value <0.001) in cell viability
following polarization with LPS and IFN-γ compared to control at 24hours post cytokine
treatment. Slight significant decrease in viability was observed in M2 macrophages
(~15%, P-value= 0.012) following IL-4 treatment for 24 hours (Fig. 14).

Control and Polarized Macrophages Infected with HSV-1 or DENV2
Morphological Changes Post-infection with HSV-1 or DENV2 and Polarization
M1 macrophages appeared enlarged, strongly adherent and vacuolated postinfection similar to uninfected M1 macrophages after 12 (Fig. 5) and 24hours (Fig. 15
and 22) of infection (HSV-1 or DENV2) and cytokine treatment. Some M2 macrophages
post-infection with HSV-1 for 24 hours appeared highly enlarged (Fig. 16) and all the M1
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macrophages appeared densely vacuolated. M2 macrophages were also similar in
morphology to uninfected macrophages. Overall morphological changes were similar
before and after DENV2 infection (Fig. 22).

CD Marker Profiling in Control and Polarized Macrophages Following HSV-1 or
DENV2 Infection
Immunofluorescence analysis of CD markers showed downregulation of CD86
expression in M1 macrophages (Fig. 18) and upregulation of CD86 expression in control
(Fig 17) and M2 (Fig. 19) upon HSV-1 infection. In case of DENV2 infection, CD86
expression is downregulated in M1 (Fig. 24) and upregulated in M2 (Fig 25)
macrophages. CD86 expression was downregulated upon HSV-1 or DENV2 infection in
M1 macrophages compared to infected control (Fig 17 and Fig 23) and M2 as well as
uninfected macrophages. CD86 expression was upregulated in M2 macrophages postinfection. CD14 expression was similar in both HSV-1 or DENV2 infected cells. But
CD14 expression was further downregulated in M1 macrophages infected with DENV2
compared to HSV-1 infected or uninfected M1 macrophages.
Flow cytometry analysis of CD markers on HSV-1 infected polarized
macrophages show that M1 macrophages exhibit upregulated expression (28.34%, Pvalue= 0.017) of CD14+-CD86+ in comparison with control. On the other hand, CD14+CD86+ expression changed insignificantly in M2 macrophages (3.04%, P-value= 0.145)
(Fig. 20 and 21). In the case of DENV2 infected macrophages, CD14+-CD86+
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expression was upregulated in M1 phenotype (36.57%, P-value= 0.013) compared to
control (Fig. 26 and 27). Also, there was a minor increase in CD14+-CD86+ HSV-1 M1
macrophages compared to uninfected M1 macrophages. CD14+-CD86+ expression
decreased slightly in DENV2 infected M2 macrophages (3.7%, P-value= 0.098)
compared to control. Overall CD14+-CD86+ expression was downregulated by about 7
times in DENV2 infected macrophage phenotypes (control and M2) compared to
uninfected or HSV-1 infected control and M2 macrophages.

Cell Viability
Cell viability studies by Trypan Blue assay showed further decrease in infected
macrophage populations compared to uninfected macrophages. Cell viability of HSV-1
infected M1 macrophages decreased significantly (43.61%, P-value<0.001) while that of
M2 macrophages was insignificant (5%, P-value= 0.116) after 12 hours of infection and
cytokine treatment (Fig. 13). DENV2 infected M1 (39.05%, P-value= 0.001) and M2
(3.11%, P-value= 0.219) macrophages also showed the same changes in cell viability as
HSV-1 infected macrophage populations after 12 hours of virus and cytokine treatment.
HSV-1 infected M1 macrophages decreased by ~80% (P-value<0.001) and insignificant
difference in M2 (P-value=0.293) compared to control (Fig. 12). Cell viability of DENV2
infected M1 macrophages decreased significantly (~70%, P-value< 0.001) after 24 hours
of infection and cytokine-treatment. Also the cell viability of DENV2 infected M2
macrophages changed insignificantly (P-value=0.054). The overall cell viability among
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the macrophage subpopulations decreased significantly in both uninfected and infected
M1 macrophages after 24 hours (Fig. 14).

SOCS Expression in Uninfected and HSV-1 or DENV2 Infected Macrophages
SOCS1 and SOCS3 expressions were determined by western blotting.
Macrophages were either unpolarized or cytokine-polarized and uninfected or infected
for 12 (Fig. 28 and 29) or 24 hours (Fig. 30 and 31). At 12 hours post cytokine
polarization and virus infection in M1 macrophages in each of the experimental groups
compared with the respective M0 cells, SOCS1 expression was significantly lower in
uninfected (P-value= 0.043), HSV-1 infected (P-value=0.001) and DENV2 infected (Pvalue<0.001). In M2 macrophages in each of the above groupings compared with
respective M0 cells, SOCS1 expression in HSV-1-infected cells decreased (P-value=
0.038); there was no significant variation in DENV2- infected M2 macrophages (Pvalue> 0.05).
At 24hours after cytokine polarization and virus infection in M1 macrophages in
each of the experimental groups compared with the respective M0 cells, SOCS3
expression was significantly lower in HSV-1 infected (P-value< 0.001) and significantly
higher in uninfected (P-value<0.001), however, an insignificant change in DENV2
infected (P-value>0.05) cells. In M2 macrophages in each of the experimental groups
compared with the respective M0 cells, SOCS3 expression was significantly higher in
uninfected (P-value=0.004) and HSV-1 infected (P-value=0.014) and significantly lower
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in DENV2 infected (P-value=0.009). The overall expression of SOCS3 was found to be
significantly higher than the expression of SOCS1 after 24 hours of cytokine treatment.
The SOCS1/SOCS3 ratio at 12 hours after infection with HSV-1 was significantly
higher (P-value= 0.004) in M1 cells than that seen for the uninfected M1 cells- while this
ratio in DENV2-infected M1 cells was significantly lower (P-value= 0.002). At this same
time, the SOCS1/SOCS3 ratios of HSV-1 or DENV2-infected M2 cells showed no
difference from uninfected M2 cells.
By 24 hours after infection the SOCS1/SOCS3 ratio of HSV-infected M1 cells to
that of uninfected M1 macrophages was significantly higher (P-value= 0.015) while
SOCS1/SOC3 ratio was no higher in DENV2-infected cells than that seen in uninfected
M1 cells. At 24 hours post infection, SOCS1/SOCS3 ratio of HSV-1-infected M2 cells
was the same as that of uninfected M2 cells. SOC1/SOCS3 ratio was significantly higher
(P-value<0.001) in DENV2-infected macrophages than in uninfected M2 cells.

Virus Replication in Polarized Macrophages
Viral titers were measured by standard plaque assay (Fig. 34). Titer for HSV-1 in
M1 macrophages was 3-fold lower than in M0 and 3.5-fold less than titer of virus in M2
cell cultures.
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DISCUSSION

In this study we found that macrophages infected with HSV-1 and DENV2 along
with cytokine induced polarization show differences in the expression of CD14 and
CD86 cell surface markers after 24 hours. In macrophages subjected to polarization with
LPS+IFN-γ for development of the M1 subpopulation and with IL-4 for polarization of
M2 cells, changes in the properties and morphology of the cells after 12 and 24 hours
were observed. M1 cells were large, elongated, vacuolated and strongly adherent. On the
other hand, the morphology of M2 macrophages was similar to control M0 cells in that
the cells were round or elongated and stellate. At these same times, cell viability of the
M1 macrophages was markedly decreased compared to control and M2 macrophages.
The results from HSV-1 plaque assay show a 3 – 3.5 fold decrease in viral titers
suggesting decrease in viral uptake and replication by M1 macrophages. This decrease
may reflect production of pro-inflammatory cytokines and cytotoxic molecules leading to
cell death and impaired virus replication.
There is a decrease in cell viability of M1 macrophages, while not in case of M2
macrophages. This decrease in M1 cell viability can be attributed to the production of
cytotoxic molecules such as the reactive oxygen-intermediates, nitric oxide and TNF-α
(Naha et al., 2010; Kyoungho et al., 2001). We know that M1 macrophages are known to
be associated with pro-inflammatory cytokines such as TNF-α and other cytotoxic
compounds such as inducible nitric oxide species (iNOS) and reactive oxygen species
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(ROS) (Schachtele et al., 2010). In future experiments, nitric oxide concentrations in the
culture can be detected by Griess reagent and the culture can be treated with a blocking
agent for iNOS (or NO inhibitors) to see if the cell viability increases. Also, TNF-α can
be neutralized by the help of anti-TNF-α antibodies which requires more than 24 hours
for action on TNF-α.
Cell-surface markers CD14 (LPS co-receptor) and CD86 (B7-2 co-stimulatory
molecule) expressions differed between polarized subsets of macrophages. It was
observed that expression of CD14 was uniformly higher in all the macrophage subtypes
as opposed to higher expression only in M1 macrophages (Gordon and Taylor, 2005).
This might be attributed to the property of RAW264.7 cells being virus transformed and
belonging to monocyte-macrophage derived lineage of cells (Raschke et al., 1978). Also
it has been found in a recent study that the RAW 264.7 cells release leukemia virus in the
culture (Hartley et al., 2008). During M1 polarization, bacterial LPS acts as a ligand
interacting with and activating CD14 and TLR4 on macrophage surface and IFN-γ along
with LPS upregulates expression of CD86 for the antigen-presenting function of
macrophages (Tapping et al., 2000; Kitchens, 2000).
Similar to the observations of Reichard (2013), CD14-CD86 expression was
higher in M1 macrophages prior to and after virus infection. These results suggest that
HSV-1 or DENV2 infection affects the ability of unpolarized or polarized RAW 264.7
macrophages to express CD14 and CD86. CD14 can implement an innate immune
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response and CD86 can mount an adaptive immune response against the virus by
promoting pro-inflammatory immune responses. CD86 is involved in B cell stimulation,
T-cell activation and maturation (Chen et al., 1994). T cells play a major role in adaptive
immunity against HSV-1 infection but not significantly against DENV2 infection
signifying the expression of CD86 on M2 macrophages (Johnson et al., 2008).
Suppressors of cytokine signaling (SOCS) proteins are antagonists of cytokine
signaling. Under normal conditions, SOCS proteins are anti-inflammatory in nature and
subject inflammatory proteins to proteasomal degradation by ubiquitylation (Yoshimura,
2003). They inhibit cytokine production thus inhibiting immune system defense against
infection by inhibiting the JAK/STAT pathway (Cooney, 2002). But in case of a viral
infection, viral proteins have ability to hijack SOCS functions making them the targets
for viral evasion in the host. SOCS proteins inhibit antiviral immune responses thus
allowing viral invasion and replication (Nowoslawski et al., 2010 In this study the overall
SOCS3 expression was higher than SOCS1 expression. SOCS3 expression in M1
macrophages is high suggesting the that viral infection activates SOCS proteins in
macrophages thus inhibiting the production of pro-inflammatory cytokines such as TNFα, IL-12, etc. and other cytotoxic agents such as iNOS and ROS by inhibiting either
MAPK pathway or IFNAR signaling cascade respectively. Thus, inhibition of proinflammatory immune responses allows virus survival in the host. Studies by Qin et al.,
2012 have shown that SOCS3 represses M1 macrophage polarization and thus inhibits
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pro-inflammatory immune responses. We determined that M1 cell viability decreased
further post-infection and that SOCS3 was upregulated in DENV2 infected M1 cells
compared to control and M2 macrophages this is in correlation with a recent study that
showed that SOCS3 is essential in regulating macrophage polarization showing SOCS
deletion induced resistance to LPS induced endotoxic shock. Another finding from this
study showed enhanced IL-4 plus IL-13 induced STAT6 phosphorylation in SOCS3
knockout macrophages (Spence et al., 2013).
In future studies, the effect of SOCS proteins upon infection can be studied with
the help of specific SOCS antagonists, on how they inhibit SOCS thus allowing release of
pro-inflammatory cytokines that are effective against viral infections. Some specific
SOCS1 antagonists such as small peptide antagonist that corresponds to the activation
loop of Jak2 can be used in future studies and SOCS expression can be observed postinfection and polarization of macrophages (Johnson et al., 2010). In the present study,
change in SOCS1 expression and not SOCS3 expression after 12 hours of treatment
stems from increasing concentrations of pro-inflammatory cytokines and ROS or iNOS
produced by IFNAR pathway may be inhibited by increasing SOCS1 (Song et al., 1998).
But 24 hours after cytokine treatment with or without infection, SOCS1 expression is
suppressed with an increase in SOCS3 activity. We assume this might be due to interregulation of SOCS1 by SOCS3 and vice versa. Also increase in SOCS3 directly affects
the MAPK pathway to inhibit pro-inflammatory cytokine production showing an
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ameliorating effect on rapid decrease in cell viability and delayed viral elimination.
Increase in SOCS1/SOCS3 ratio after 24hours of cytokine polarization and virus
challenge in M1 macrophages in HSV-1 infected cells suggests SOCS3 may have
compromised following infection resulting in inhibition of JAK/STAT as well as IFNAR
pathway of pro-inflammatory cytokines, ROS and iNOS production.
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Figure 4. DENV2 Plaque assay. A) DENV2 plaque assay performed using crystal violet
staining of infected Vero cells after 5 days of incubation. (PFU= 6.9 x 1010) B) Flow
cytometry analysis using FITC-4G2 mAb (DENV2 specific) monoclonal antibody for
quantification of infected cells after 24 hours of incubation. (FACS infectious
units/ml=7.3 x 1010 )
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Figure 5. Morphological changes exhibited by RAW 264.7 macrophage sub-populations
12 hours post cytokine treatment with or without infection. M1 macrophages (uninfected
or infected) exhibited cytosolic vacuoles as early as 12 hours post LPS and IFN-γ
treatment. IL-4 treated macrophages (M2) showed no visible changes in morphology as
compared to control macrophages.
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Figure 6. RAW 264.7 macrophages: Top, Untreated control cells Middle, IFN-γ and LPS
treated (M1) and Bottom, IL-4 treated (M2). Right, Respective experimental groups
phalloidin stained for actin arrangement. M1 macrophages appeared enlarged, irregularly
shaped, strongly adherent, and highly vacuolated. M2 macrophages exhibited
morphology similar to that of control cells.
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Figure 7. LPS + IFN-γ treated RAW 264.7 macrophages: Left, Field view of M1
macrophages. Right, Enlarged view showing visible vacuolated M1 macrophages.
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Figure 8. RAW 264.7 macrophages untreated for 24 hours and: A, Actin stained with
Texas-Red Phalloidin X for B, stained with FITC conjugated anti-CD14 antibodies C,
stained with Brilliant violet conjugated anti-CD86 antibodies D, CD14, CD86, and
Phalloidin merged image. M1 macrophages showed slight CD86 expression (Scale bar
=50μm).
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Figure 9. RAW 264.7 macrophages treated with LPS and IFNg for 24 hours and: A,
Actin stained with Texas-Red Phalloidin X for B, stained with FITC conjugated antiCD14 antibodies C, stained with Brilliant violet conjugated anti-CD86 antibodies D,
CD14, CD86, and Phalloidin merged image. M1 macrophages showed increased CD86
expression compared to control macrophages (Scale bar =50μm).
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Figure 10. RAW 264.7 macrophages treated with IL4 for 24 hours and: A, Actin stained
with Texas-Red Phalloidin X for B, stained with FITC conjugated anti-CD14 antibodies
C, stained with Brilliant violet conjugated anti-CD86 antibodies D, CD14, CD86, and
Phalloidin merged image. M2 macrophages showed very low or no CD86 expression
compared to control and M1 macrophages (Scale bar =50μm).
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Figure 11. Flow cytometry analysis of CD14-CD86 expression levels in M1, M2, and
control macrophages. Negative isotype control CD14 and CD86 antibodies were used to
set quadrants. Flow cytometry analysis of CD markers on uninfected polarized
macrophages show that M1 macrophages exhibit upregulation of CD14+-CD86+
expression (33.37%, P-value< 0.001) when compared to control macrophages.
Conversely, M2 macrophages showed insignificant changes in CD14+-CD86+
expression (1.14%, P-value= 0.319) when compared to untreated control.
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Figure 12. CD14+-CD86+ expression profile of uninfected control, M1 and M2
macrophages. CD14+-CD86+ expression is significantly higher in M1 macrophages (Pvalue< 0.001), while the difference in CD14+-CD86+ expression in M2 macrophages is
insignificant (P=value> 0.05).
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Figure 13. Cell viability studies 12hours post cytokine treatment with or without
infection. Cell viability of HSV-1 (43.61%, P-value<0.001) infected M1 macrophages
decreased significantly while that of M2 macrophages was insignificant (5%, P-value=
0.116) after 12 hours of infection and cytokine treatment. DENV2 infected M1 (39.05%,
P-value= 0.001) and M2 (3.11%, P-value= 0.219) macrophages also the same changes in
cell viability as HSV-1 infected macrophage populations after 12 hours of DENV2
infection and cytokine treatment. Cell viability of uninfected M1 (73.76%, P-value<
0.001) and M2 (47.41%, P-value= 0.001) macrophages decreased significantly compared
to control.

43

Cell Viability Following Polarization (24 hours)
120

Cell Viability of HSV-1 Infected Cells
Following Polarization (24 hours)

*

120

**

*
Percentage of Viable Cells

Percentage of Viable Cells

100

80

60

40

20

100

80

60

40

20

0

0

Control

M1

M2

Control

M1

M2

Cell Viability of DENV2 Infected Cells
Following Polarization (24 hours)
120

Percentage of Viable Cells

*
**

100

80

60

40

20

0

Control

M1

M2

Figure 14. Cell viability studies 24 hours post cytokine treatment with or without
infection. Cell viability of DENV2 infected M1 macrophages decreased significantly
(~70%, P-value< 0.001) after 24 hours of infection and cytokine-treatment. Also the cell
viability of DENV infected M2 macrophages changed insignificantly (P-value=0.054).
The overall cell viability among the macrophage subpopulations decreased significantly
in both uninfected and infected M1 macrophages after 24 hours. HSV-1 infected M1
macrophages decreased by ~80% (P-value<0.001) and insignificant difference in M2 (Pvalue=0.293) compared to control. Uninfected M1 macrophages showed highly
significant (96%, P-value< 0.001) decrease in viability compared to control.
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Figure 15. HSV-1 infected RAW 264.7 macrophages: Top, Unpolarized control cells
Middle, IFN-γ and LPS treated (M1) and Bottom, IL-4 treated (M2). Right, Respective
experimental groups phalloidin stained for actin arrangement. Few M2 macrophages
appeared enlarged compared to control as well as uninfected control and M2 cells.
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Figure 16. HSV-1 infected M2 polarized RAW 264.7 macrophages.
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Figure 17. RAW 264.7 infected with HSV-1 for 24 hours and: A, Actin stained with
Texas-Red Phalloidin X for B, stained with FITC conjugated anti-CD14 antibodies C,
stained with Brilliant violet conjugated anti-CD86 antibodies D, CD14, CD86, and
Phalloidin merged image. Control macrophages showed increased CD86 expression
compared to uninfected control macrophages (Scale bar =50μm).
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Figure 18. RAW 264.7 macrophages infected with HSV-1 and treated with LPS and
IFN-γ for 24 hours and: A, Actin stained with Texas-Red Phalloidin X for B, stained with
FITC conjugated anti-CD14 antibodies C, stained with Brilliant violet conjugated antiCD86 antibodies D, CD14, CD86, and Phalloidin merged image. M1 macrophages
showed decrease in CD86 expression compared to uninfected M1 macrophages (Scale
bar =50μm).
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Figure 19. RAW 264.7 macrophages infected with HSV-1 and treated with IL-4 for 24
hours and: A, Actin stained with Texas-Red Phalloidin X for B, stained with FITC
conjugated anti-CD14 antibodies C, stained with Brilliant violet conjugated anti-CD86
antibodies D, CD14, CD86, and Phalloidin merged image. M2 macrophages showed
increase in CD86 expression compared to uninfected M2 macrophages (Scale bar
=50μm).
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Figure 20. Flow cytometry analysis of CD14-CD86 expression levels in HSV-1 infected
M1, M2, and control macrophages. Negative isotype control CD14 and CD86 antibodies
were used to set quadrants. CD14+-CD86+ expression in M1 macrophages was
significantly upregulated (28.34%, P-value= 0.017) compared to control macrophages.
On the other hand, CD14+-CD86+ expression changed insignificantly in M2 macrophages
(3.04%, P-value= 0.145). CD14+-CD86+ expression levels increased in all three
experimental groups when compared to respective uninfected groups. (P-value<0.05 is
significant)
50

Figure 21. CD14+-CD86+ expression profile of HSV-1 infected control, M1 and M2
macrophages. CD14+-CD86+ expression is significantly higher in M1 macrophages (Pvalue= 0.017), while the difference in CD14+-CD86+ expression in M2 macrophages is
insignificant (P=value> 0.05).
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Figure 22. DENV2 infected RAW 264.7 macrophages: Top, Unpolarized control cells
Middle, IFN-γ and LPS treated (M1) and Bottom, IL-4 treated (M2). Right, Respective
experimental groups phalloidin stained for actin arrangement.
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Figure 23. RAW 264.7 macrophages infected with DENV2 for 24 hours and: A, Actin
stained with Texas-Red Phalloidin X for B, stained with FITC conjugated anti-CD14
antibodies C, stained with Brilliant violet conjugated anti-CD86 antibodies D, CD14,
CD86, and Phalloidin merged image. Control macrophages showed expression patterns
similar to uninfected control macrophages (Scale bar =50μm).
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Figure 24. RAW 264.7 macrophages infected with DENV2 and treated with LPS and
IFNg for 24 hours and: A, Actin stained with Texas-Red Phalloidin X for B, stained with
FITC conjugated anti-CD14 antibodies C, stained with Brilliant violet conjugated antiCD86 antibodies D, CD14, CD86, and Phalloidin merged image. M1 macrophages
showed decrease in CD86 expression compared to uninfected M1 macrophages (Scale
bar =50μm).
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Figure 25. RAW 264.7 macrophages infected with DENV2 and treated with IL4 for 24
hours and: A, Actin stained with Texas-Red Phalloidin X for B, stained with FITC
conjugated anti-CD14 antibodies C, stained with Brilliant violet conjugated anti-CD86
antibodies D, CD14, CD86, and Phalloidin merged image. M2 macrophages showed
increase in CD86 expression compared to uninfected M2 macrophages (Scale bar
=50μm).
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Figure 26. Flow cytometry analysis of CD14-CD86 expression levels in DENV2
infected M1, M2, and control macrophages. Negative isotype control CD14 and CD86
antibodies were used to set quadrants. CD14+-CD86+ expression levels in all three
experimental groups when compared to respective uninfected groups. M1 macrophages
had a significant increase (36.57%, P-value= 0.013) in the number of CD14+-CD86+ cells
when compared to control cells and a slight increase in the number of CD14+-CD86+ cells
when compared to uninfected M1 cells. While there was slight significant decrease
(3.7%, P-value= 0.098) in CD14+-CD86+ expression M2 macrophages. (P-value< 0.05 is
significant)
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Figure 27. CD14+-CD86+ expression profile of DENV2 infected control, M1 and M2
macrophages. CD14+-CD86+ expression is significantly higher in M1 macrophages (Pvalue=0.01), while the difference in CD14+-CD86+ expression in M2 macrophages is
insignificant (P=value> 0.05).
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Figure 28. SOCS1 expression was analyzed by western blotting. Lysates were prepared
from RAW 264.7 cells 12 hours after exposure to cytokine polarization and virus
infection and western blotted. In M1 macrophages in each of the above groupings
compared with the respective M0 cells, SOCS1 expression was significantly lower in
uninfected (P-value= 0.043), HSV-1 infected (P-value=0.001) and DENV2 infected (Pvalue<0.001). In M2 macrophages in each of the above groupings compared with
respective M0 cells, SOCS1 expression in HSV-1-infected cells decreased (P-value=
0.038); there was no significant variation in DENV2- infected M2 macrophages (Pvalue> 0.05). (P-value<0.05 is significant) (P-values were calculated individually for
each experimental group)
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Figure 29. SOCS3 expression was analyzed by western blotting. Lysates were prepared
from RAW 264.7 cells 12 hours after exposure to cytokine polarization and virus
infection and western blotted. In M1 macrophages in each of the above groupings
compared with the respective M0 cells, SOCS3 expression was significantly lower in
HSV-1 infected (P-value< 0.001) and significantly higher in uninfected (P-value<0.001),
however, an insignificant change in DENV2 infected (P-value>0.05) cells. In M2
macrophages in each of the above groupings compared with the respective M0 cells,
SOCS3 expression was significantly higher in uninfected (P-value=0.004) and HSV-1
infected (P-value=0.014) and significantly lower in DENV2 infected (P-value=0.009).
(P-value<0.05 is significant) (P-values were calculated individually for each experimental
group)
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Figure 30. SOCS1 expression was analyzed by western blotting. Lysates were prepared
from RAW 264.7 cells 24 hours after exposure to cytokine polarization and virus
infection and western blotted. In M1 macrophages in each of the above groupings
compared with the respective M0 cells, SOCS1 expression was significantly lower in
uninfected (P-value= 0.003) and DENV2 infected (P-value=0.002), however, change was
insignificant in HSV-1 infected (P-value>0.05). In M2 macrophages in each of the above
groupings compared with respective M0 cells, SOCS1 expression in HSV-1-infected and
DENV2 infected cells was insignificant (P-value>0.05), however, significantly higher in
uninfected (P-value= 0.038). (P-value<0.05 is significant) (P-values were calculated
individually for each experimental group)
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Figure 31. SOCS3 expression was analyzed by western blotting. Lysates were prepared
from RAW 264.7 cells 24 hours after exposure to cytokine polarization and virus
infection and western blotted. In M1 macrophages in each of the above groupings
compared with the respective M0 cells, SOCS3 expression was significantly lower in
uninfected (P-value= 0.001), HSV-1 infected (P-value<0.001) and DENV2 infected (Pvalue=0.016) M1 macrophages. In M2 macrophages in each of the above groupings
compared with the respective M0 cells, SOCS3 expression was significantly higher in
uninfected (P-value=0.002) and DENV2 infected (P-value=0.006) and significantly lower
in HSV-1 infected (P-value=0.002). (P-value<0.05 is significant) (P-values were
calculated individually for each experimental group)
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Figure 32. The ratio of SOCS1 and SOCS3 were plotted for different experimental
groups at 12 hours after exposure to cytokine polarization and virus infection as shown
above. In M1 macrophages in each of the above groupings compared with the respective
M0 cells, the ratio of SOCS1/SOCS3 was significantly lower in DENV2 infected cells
(P-value= 0.003), however, change was insignificant in uninfected and HSV-1 infected
cells (P-value>0.05). In M2 macrophages the ratio of SOCS1/SOCS3 was significantly
lower in HSV-1 infected (P-value= 0.011), however, change was insignificant in
uninfected and DENV2 infected cells (P-value>0.05). (P-value<0.05 is significant) (Pvalues were calculated individually for each experimental group)
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Figure 33. The ratio of SOCS1 and SOCS3 were plotted for different experimental
groups at 24 hours after exposure to cytokine polarization and virus infection as shown
above. In M1 macrophages in each of the above groupings compared with the respective
M0 cells, the ratio of SOCS1/SOCS3 was significantly lower in uninfected (P-value=
0.001) and DENV2 infected cells (P-value= 0.013), however, there was a significant
increase in HSV-1 infected cells (P-value=0.02). In M2 macrophages the ratio of
SOCS1/SOCS3 was significantly higher in HSV-1 infected (P-value= 0.003), however,
change was insignificant in uninfected cells (P-value>0.05) and DENV2 infected (Pvalue> 0.05) cells. (P-value<0.05 is significant) (P-values were calculated individually
for each experimental group)
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Control

M1

M2

No virus

100

22.8

53.3

HSV-1

61

12.6

62

DENV2

70

26.9

61.9

Cell Viability
(%)

Control

M1

M2

No virus

100

45.1

73.8

HSV-1

11.4

12.9

11.1

DENV2

85.8

49.3

58.2

Cell Viability
(%)
(12 hours)

(24 hours)

Table 1. Shows the percentage cell viability in no virus treated, HSV-1 treated and
DENV2 treated macrophage populations 12 hours and 24 hours post-cytokine treatment
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Table 2. Shows the percentage of SOCS1 and SOCS3 expression in no virus treated,
HSV-1 treated and DENV2 treated macrophage populations 24 hours post-cytokine
treatment
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10-2
10-2
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Fold
Change
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-

Figure 34. HSV-1 titers in infected macrophage subsets at 24 hours post infection with
0.1 MOI HSV-1. 3 or 3.5 fold lower virus yield was seen in culture fluids of M1 cells
compared with either M0 or M2 cell cultures, respectively.
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